| 28.7 0.37 (1.31%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.01 |
1-year : | 36.23 |
| Resists | First : | 29.97 |
Second : | 31.02 |
| Pivot price | 29.48 |
|||
| Supports | First : | 28.29 | Second : | 23.53 |
| MAs | MA(5) : | 28.89 |
MA(20) : | 29.67 |
| MA(100) : | 29.89 |
MA(250) : | 34.1 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8.1 |
D(3) : | 12.4 |
| RSI | RSI(14): 41.6  |
|||
| 52-week | High : | 42.72 | Low : | 26.31 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GMAB ] has closed above bottom band by 14.5%. Bollinger Bands are 27.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.82 - 29 | 29 - 29.16 |
| Low: | 28.04 - 28.24 | 28.24 - 28.44 |
| Close: | 28.38 - 28.69 | 28.69 - 28.98 |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Fri, 19 Apr 2024
Genmab A/S (NASDAQ:GMAB) Expected to Post FY2024 Earnings of $0.88 Per Share - MarketBeat
Thu, 18 Apr 2024
Simplicity Solutions LLC Lowers Stock Position in Genmab A/S (NASDAQ:GMAB) - Defense World
Wed, 17 Apr 2024
Genmab A/S (NASDAQ:GMAB) Shares Gap Down to $29.43 - MarketBeat
Tue, 16 Apr 2024
Genmab Reports Strong Q1 Sales of DARZALEX - TipRanks.com - TipRanks
Tue, 16 Apr 2024
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024 - GlobeNewswire
Mon, 15 Apr 2024
Genmab Advances Share Buy-back Program - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 651 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 7.2 (%) |
| Shares Short | 2,400 (K) |
| Shares Short P.Month | 1,860 (K) |
| EPS | 0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 483.85 |
| Profit Margin | 26.4 % |
| Operating Margin | 35.7 % |
| Return on Assets (ttm) | 10.1 % |
| Return on Equity (ttm) | 14.7 % |
| Qtrly Rev. Growth | -8.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 25.31 |
| EBITDA (p.s.) | 8.54 |
| Qtrly Earnings Growth | 24.6 % |
| Operating Cash Flow | 7,380 (M) |
| Levered Free Cash Flow | 5,290 (M) |
| PE Ratio | 30.21 |
| PEG Ratio | 2 |
| Price to Book value | 0.05 |
| Price to Sales | 1.13 |
| Price to Cash Flow | 2.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|